Doximity acquires AI startup Pathway Medical for $63 million

Work On Thursday, Startup Pathway Medical is a deeper diving into artificial intelligence by announcing that it was purchased for $ 63 million.

Pathway has created an AI -supported clinical reference tool that doctors can use to ask questions about instructions, drugs and trials. Pathway’s answers were synthesized from the medical literature, and Doximity said that the Montreal -based initiative had one of the largest structured data clusters in medicine.

The platform of Doximity, which has been defined as LinkedIn for doctors for years, helps clinicians to stay up -to -date in medical news, manage, find referrals, and make telealth appointments with patients. With the acquisition of Pathway, Doximity hopes that doctors will return to the platform to answer clinical questions.

“We hunted high and low, and I think we found the best company in the field to answer the questions of doctors by using AI,” Jeff Tanney, the founding partner and CEO of Doximity, said in an interview.

Doximity said the agreement was closed with an additional equity grant up to 26 million dollars in late July and up to $ 37 million.

Değerli The integration of Doximity with Pathway continues, Tangney and companies are testing a product combined with thousands of doctors.

In the meantime, patients return to AI tools and chat boots with more regularity for answers to health -related questions, which has potentially laborious results due to the possibility of incorrect suggestions.

During a live broadcast on Thursday, when Openai announced the new model GPT-5, CEO Sam Altman said that health queries were one of the largest chatgpt usage categories. A writing In X, he adds that the new model is “much better” in that area.

Doximity has a free AI product that doctors can use to create insurance letters and summarize patient graphics and reports. Doximity’s chief clinical experience officer. Amit Phull said that Pathway would bring additional “solid” to the data of Doximity at the back end.

“What the road brings to this side or this marriage is that they have a very solid rear end data set that directs dosages to the literature,” Phull an interview. He said.

Pathway’s model received 96% of the US Medical Licensing Exam criterion.

Doximity, which was opened to the public in 2021, increased by 90% in 2024 and saw the 10% climb of stocks this year. The company has a market value of about $ 11 billion.

Doximity shares increased approximately 6% in expanded transactions on Thursday after the company reported. financial first quarter Results exceeding predictions. According to LSEG, the income increased by 15% compared to the previous year, while analysts expected $ 139.5 million sales. 36 cents over the average prediction of 30 cents per share.